Athira Pharma Q2 net loss $14.0M; advances Alzheimer's trials; open label extension initiated

LeonaBio, Inc.

Net loss $14.0M ($0.38/sh) vs $2.0M loss in Q2 2020; R&D expenses $12.0M (up from $1.7M).
Cash and investments $349.9M as of June 30, 2021, up from $268.2M at year-end 2020.
Open label extension started for LIFT-AD and ACT-AD trials; topline data ACT-AD by H1 2022, LIFT-AD by end 2022.
Phase 2 trial of ATH-1017 for Parkinson's disease dementia targeted to start by end 2021; IND for ATH-1020 by end 2021.
COO Mark Litton assumes day-to-day leadership; board chair Tadataka Yamada died; Kelly Romano appointed chair.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.